LungLife AI, Inc.

LSE LLAI.L

LungLife AI, Inc. Revenue Per Share for the year ending December 31, 2023: USD 0.00

LungLife AI, Inc. Revenue Per Share is USD 0.00 for the year ending December 31, 2023, a 91.63% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

LungLife AI, Inc. Revenue Per Share for the year ending December 31, 2022 was USD 0.00, a -92.36% change year over year.
LungLife AI, Inc. Revenue Per Share for the year ending December 31, 2021 was USD 0.01, a 53.03% change year over year.
LungLife AI, Inc. Revenue Per Share for the year ending December 31, 2020 was USD 0.01, a 50.32% change year over year.
LungLife AI, Inc. Revenue Per Share for the year ending December 31, 2019 was USD 0.01, a -86.10% change year over year.

Key data

Date	Revenue Per Share	Dividend Per Share	Free Cash Flow Per Share	Return on Assets (ROA)

LSE: LLAI.L

LungLife AI, Inc.

CEO	Dr. Paul Pagano Ph.D.
IPO Date	July 8, 2021
Location	United States
Headquarters	2545 West Hillcrest Drive
Employees	8
Sector	Technology
Industries Artificial Intelligence (AI) Biotechnology

Description

LungLife AI, Inc., a cancer diagnostics company, develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology. It engages in developing LungLB, an AI enhanced, blood-based test to utilize machine learning to identify and count CTCs with reducing operator hands-on time and increasing test performance. The company was formerly known as Cynvenio Biosystems, Inc. and changed its name to LungLife AI, Inc. in May 2019. The company is based in Thousand Oaks, California.

Key trends

Past 5 years